Adi Hoess, Affimed CEO
#ASH22: 'Not so surprising': With lack of durability, Affimed scraps monotherapy plans in favor of NK cell combo
NEW ORLEANS — Affimed won’t move ahead with an accelerated approval application for its drug AFM13, an innate cell engager it was testing in relapsed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
